Brief: Bio-Path Holdings Completes First Dose Cohort In Phase 1 Clinical Trial For Blood Cancer Treatment
10/01/2024 12:36
Jan 10 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES COMPLETION OF FIRST DOSE
COHORT IN
PHASE 1 CLINICAL TRIAL EVALUATING BP1002 TO TREAT
REFRACTORY/RELAPSED LYMPHOMA AND REFRACTORY/RELAPSED CHRONIC
LYMPHOCYTIC LEUKEMIA PATIENTS
Source text for Eikon: ID:nGNX696pc1
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia